The 19th Clinical Trials on Alzheimer's Disease Conference (CTAD) will be held in Boston, United States, where SYSMEX CORPORATION is scheduled to present the latest data on Alzheimer's disease diagnosis. The presentation will focus primarily on CSF- and plasma-related biomarkers.
The 19th Clinical Trials on Alzheimer's Disease Conference (CTAD) will be held in Boston, United States, where SYSMEX CORPORATION will disclose data related to Alzheimer's disease diagnosis. The presentation will focus on the development and analytical performance evaluation of a highly sensitive automated immunoassay for p-tau205.
The session's poster number is Biomarkers (CSF & Plasma) / P288, and the presenter is Mori Masashi (森 雅志) of SYSMEX CORPORATION. The presentation will take place between 7:15 a.m. and 5:30 p.m. on 18 November (Wednesday), local time.
The article also includes related information on SYSMEX CORPORATION's initiatives, employees' views, and the organization of financial and non-financial information, and reports on the disclosure of the latest data at CTAD.